Moderna said on Monday its influenza vaccine was found to be 26.6% more effective than an approved annual flu shot from GSK ...

A new study by the University of Oxford, published in the journal npj Vaccines, shows that a vaccine against respiratory ...

Gilead Sciences has blamed the low rate of respiratory syncytial virus (RSV) infections last season for ending two midstage ...

Recent studies have shown convincingly that vaccines against shingles (Herpes zoster) reduce the risk of dementia.

A new ESC Clinical Consensus Statement published in the European Heart Journal discusses the key role of vaccination in ...

The recommendation for Enflonsia is indicated for respiratory syncytial virus prevention in infants under eight months of age, expanding protection options ahead of the 2025–2026 season.

The ACIP is recommending the use of Enflonsia for the prevention of RSV lower respiratory tract disease in infants younger than 8 months.

The mRNA drug developer said it will begin discussing approval with the FDA, which has adopted stricter vaccine review ...

An outside group of experts agreed that the CDC should recommend a new antibody drug that offers protection against RSV for ...

The eight new ACIP members met for the first time June 25 after Kennedy fired all 17 original members of the committee June 9 ...

A group of outside advisers to the US Centers for Disease Control and Prevention voted 5-2 to recommend use of a new shot ...

The FDA delivered two notable approvals for RSV immunization, UroGen overcame a negative advisory committee vote to secure an ...